No Data
Jiangxi Synergy Pharmaceutical (300636.SZ): Sales of new varieties will continue to grow in 2025.
On January 8, Gelonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) recently stated in an investor relations activity that the sales performance of new products in Q4 was better than in Q3, and the sales of new products will continue to grow in 2025, with growth in the high-end market surpassing that of Emerging Markets.
Jiangxi Synergy Pharmaceutical (300636.SZ): It is expected that the production capacity utilization rate of Phase I of the second factory will exceed 60% in 2025.
On January 8, Gelonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) stated during a recent investor relation activity that the capacity utilization rate of Phase I of the second factory area in the second half of 2024 is around 60% (officially starting production in the second half of the year), and it is expected that the capacity utilization rate will exceed 60% in 2025; all seven workshops of Phase II of the second factory area have completed civil construction, with the installation of equipment starting in two workshops after the Spring Festival, and it is expected that production capacity will be formed in the fourth quarter of 2025.
Jiangxi Synergy Pharmaceutical (300636.SZ): The revenue from CMO/CDMO Business in 2024 is expected to decrease significantly compared to the previous year.
Gelonghui, January 8 - Jiangxi Synergy Pharmaceutical (300636.SZ) recently stated in an investor relations event that a major original research client canceled all Orders from the second quarter and thereafter, leading to a significant year-on-year decrease in CMO/CDMO Business revenue for the whole year. In 2025, some new projects in this Sector will launch, and revenue is expected to be higher than in 2024.
Jiangxi Synergy Pharmaceutical (300636.SZ): The overall supply of celecoxib will be in a state of shortage in 2024, and the company is considering expanding production.
On January 8, Gelonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) recently stated in its investor relations activities that the prices of old products are still at a low level overall, that there will be a significant increase in gabapentin sales in 2024, but the prices are declining; that there will be an overall supply shortage of celecoxib in 2024, and that the company is considering expanding production.
Jiangxi synergy pharmaceutical (300636.SZ): Rivaroxaban tablets have obtained the pharmaceutical registration certificate.
On November 22, Gelonhui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently received the 'Pharmaceutical Registration Certificate' of Rivaroxaban issued by the National Medical Products Administration. Rivaroxaban is an oral Xa inhibitor, clinically used for the prevention and treatment of thrombotic events in adults and children. According to data from the Yaodu database, the sales of Rivaroxaban tablets in urban, county, and township public hospitals in China in 2023 were approximately 1.74 billion yuan.
Jiangxi Synergy Pharmaceutical (300636.SZ): The active pharmaceutical ingredient of valsartan potassium has been approved by the CDE.
On November 13th, GeLongHui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently obtained approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) through the 'Active Pharmaceutical Ingredient Registration Information Disclosure' platform. The active pharmaceutical ingredient 'Valsartan Potassium' submitted by the company has been approved by the CDE. Valsartan Potassium is used to treat primary hypertension in adults.
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%
